Display options
Cite
Kuo C, Tsai CC, Chen CA, et al. Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients. Acta Cardiol Sin. 2017;33(2):188-194doi: 10.6515/acs20160818b.
Kuo, C., Tsai, C. C., Chen, C. A., Tsai, Y. F., & Chen, Y. H. (2017). Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients. Acta Cardiologica Sinica, 33(2), 188-194. https://doi.org/10.6515/acs20160818b
Kuo, Chieh, et al. "Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients." Acta Cardiologica Sinica vol. 33,2 (2017): 188-194. doi: https://doi.org/10.6515/acs20160818b
Kuo C, Tsai CC, Chen CA, Tsai YF, Chen YH. Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients. Acta Cardiol Sin. 2017 Mar;33(2):188-194. doi: 10.6515/acs20160818b. PMID: 28344423; PMCID: PMC5364161.
Copy Download .nbib Format: NLM
Share it on

Acta Cardiol Sin. 2017 Mar;33(2):188-194. doi: 10.6515/acs20160818b.

Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients.

Acta Cardiologica Sinica

Chieh Kuo, Chiang-Chin Tsai, Chien-An Chen, Yueh-Feng Tsai, Yen-Hsun Chen

Affiliations

  1. Department of Cardiology.
  2. Department of Surgery, Tainan Sinlau Hospital; ; Department of Health Care Administration, Chang Jung Christian University.
  3. Department of Health Care Administration, Chang Jung Christian University; ; Department of Nephrology, Tainan Sinlau Hospital, Tainan, Taiwan.
  4. Department of Nephrology, Tainan Sinlau Hospital, Tainan, Taiwan.

PMID: 28344423 PMCID: PMC5364161 DOI: 10.6515/acs20160818b

Abstract

BACKGROUND: Arterial stiffness is a determinant of cardiovascular disease in end stage renal disease. Hemodialysis patients may develop anti-platelet factor 4/heparin antibody (PF4-H Ab) because of heparin treatment in dialysis. We tested whether PF4-H Ab was associated with progression of arterial stiffness in a 3-year follow-up.

METHODS: We enrolled 74 hemodialysis patients and studied their clinical, biochemical and arterial stiffness measurement with brachial-ankle pulse wave velocity (baPWV) over 3 years. Baseline and changes in baPWV after 3 years (ΔbaPWV) were collected and compared with related clinical and biochemical parameters. PF4-H Ab was evaluated by the enzyme-linked immunosorbent assay and titer ≥ 0.4 was defined to have PF4-H Ab.

RESULTS: We found a positive PF4-H Ab status in 25 of 74 patients. Mean baPWV was 16.1 ± 3.8 (m/s) at baseline and 17.6 ± 4.0 (m/s) after 3 years. Mean ΔbaPWV was 3.4 ± 2.2 (m/s) in the PF4-H Ab positive group, and 0.6 ± 1.2 (m/s) in the PF4-H Ab negative group. Baseline baPWV was only significantly associated with age (β = 0.49, p < 0.01). ΔbaPWV was significantly different between the PF4-H Ab positive and negative groups (p < 0.01). In multivariate regression analysis, only PF4-H Ab was positively associated with ΔbaPWV (β = 0.71, p < 0.01).

CONCLUSIONS: Our study concluded that PF4-H Ab was associated with progression of arterial stiffness in hemodialysis patients.

Keywords: Anti-platelet factor 4-heparin antibody; Arterial stiffness; Brachial-ankle pulse wave velocity; Hemodialysis

References

  1. Mayo Clin Proc. 2005 Aug;80(8):995-1000 - PubMed
  2. Diabetes. 2003 Feb;52(2):448-52 - PubMed
  3. Thromb Haemost. 2008 Sep;100(3):498-504 - PubMed
  4. Hemodial Int. 2005 Oct;9 Suppl 1:S2-7 - PubMed
  5. Int Urol Nephrol. 2015 Sep;47(9):1565-70 - PubMed
  6. Int J Cardiol. 2005 Jan;98(1):99-105 - PubMed
  7. J Am Soc Nephrol. 2005 Nov;16(11):3381-8 - PubMed
  8. Scand J Work Environ Health. 2005 Oct;31(5):352-9 - PubMed
  9. Pathophysiol Haemost Thromb. 2006;35(6):445-50 - PubMed
  10. Circulation. 1999 May 11;99(18):2434-9 - PubMed
  11. Clin Exp Nephrol. 2012 Apr;16(2):300-5 - PubMed
  12. Blood. 2008 Oct 1;112(7):2607-16 - PubMed
  13. Clin Chem. 2013 Aug;59(8):1166-74 - PubMed
  14. Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1192-200 - PubMed
  15. J Clin Lab Anal. 2005;19(5):189-95 - PubMed
  16. PLoS One. 2013 Apr 30;8(4):e62239 - PubMed
  17. Hypertension. 2003 Nov;42(5):1050-65 - PubMed
  18. Nephron. 1998;79(2):245-6 - PubMed
  19. Nephrol Dial Transplant. 2007 Jun;22(6):1680-4 - PubMed
  20. Kidney Int. 1997 Jun;51(6):1678-95 - PubMed
  21. Diabetes Res Clin Pract. 2004 Oct;66(1):57-61 - PubMed
  22. Nephrol Dial Transplant. 2005 Feb;20(2):444-6 - PubMed
  23. Nephrol Dial Transplant. 2012 May;27(5):1873-80 - PubMed
  24. Surgery. 2004 Oct;136(4):848-53 - PubMed
  25. Kidney Int. 2003 May;63(5):1852-60 - PubMed
  26. Int Immunol. 2002 Feb;14(2):121-9 - PubMed
  27. Int Urol Nephrol. 2015 Nov;47(11):1847-53 - PubMed
  28. Kidney Int. 2008 Jan;73(2):213-9 - PubMed
  29. Hypertens Res. 2003 Aug;26(8):615-22 - PubMed
  30. Clin Neurol Neurosurg. 2008 Jun;110(6):599-604 - PubMed
  31. Atherosclerosis. 2003 Feb;166(2):303-9 - PubMed
  32. Am J Kidney Dis. 2005 Oct;46(4):688-96 - PubMed
  33. Thromb Haemost. 2008 Oct;100(4):678-84 - PubMed
  34. J Pediatr. 2007 Mar;150(3):247-51 - PubMed
  35. Prev Med. 2004 Dec;39(6):1135-42 - PubMed

Publication Types